Steroid-induced glaucoma

Summary

Steroid-induced glaucoma (MONDO:0004930) is a disease and 4 clinical trials. Top therapeutic interventions include dexamethasone. A subtype of glaucoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	steroid-induced glaucoma
Mondo ID	MONDO:0004930
DOID	DOID:9946
SNOMED CT	1654001
UMLS	C0339578
MedGen	573238
Is cancer (heuristic)	no

Also known as: corticosteroid-induced glaucoma

Disease family

This is a subtype of glaucoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › disorder of orbital region › eye disorder › glaucoma › steroid-induced glaucoma

Related subtypes (10): glaucomatous atrophy of optic disk, hypersecretion glaucoma, aqueous misdirection, phacogenic glaucoma, traumatic glaucoma, angle-closure glaucoma, borderline glaucoma, open-angle glaucoma, hereditary glaucoma, secondary early-onset glaucoma

Subtypes (1): residual stage corticosteroid-induced glaucoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE4	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04075227	PHASE4	COMPLETED	Topical 0.2% Loteprednol Etabonate vs. Topical 0.1% Dexamethasone in Impending Recurrent Pterygium
NCT01912638	PHASE1/PHASE2	COMPLETED	Trabeculectomy With Ologen Collagen Implant vs Trabeculectomy With Provisc in Steroid Induced Glaucoma
NCT04593745	Not specified	UNKNOWN	Intraocular Pressure in Children With Acute Lymphoblastic Leukemia (ALL) Treated With High Dose Steroids
NCT04673201	Not specified	UNKNOWN	Management Steroid Induced Glaucoma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DEXAMETHASONE	4	1